{
  "id": "61f7d6db882a024a10000037",
  "type": "summary",
  "question": "What is the mechanism of action of Toripalimab?",
  "ideal_answer": "Toripalimab is IgG4 monoclonal antibody targeting PD-1, which has been approved for treatment of patients with metastatic melanoma after previous systemic therapy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30892132",
    "http://www.ncbi.nlm.nih.gov/pubmed/34894461",
    "http://www.ncbi.nlm.nih.gov/pubmed/34521188",
    "http://www.ncbi.nlm.nih.gov/pubmed/32224416",
    "http://www.ncbi.nlm.nih.gov/pubmed/34504425",
    "http://www.ncbi.nlm.nih.gov/pubmed/32406293",
    "http://www.ncbi.nlm.nih.gov/pubmed/32943323",
    "http://www.ncbi.nlm.nih.gov/pubmed/34678907",
    "http://www.ncbi.nlm.nih.gov/pubmed/32589350",
    "http://www.ncbi.nlm.nih.gov/pubmed/32487680",
    "http://www.ncbi.nlm.nih.gov/pubmed/32874831",
    "http://www.ncbi.nlm.nih.gov/pubmed/34603452",
    "http://www.ncbi.nlm.nih.gov/pubmed/31403867",
    "http://www.ncbi.nlm.nih.gov/pubmed/32445174",
    "http://www.ncbi.nlm.nih.gov/pubmed/31236579",
    "http://www.ncbi.nlm.nih.gov/pubmed/34632814",
    "http://www.ncbi.nlm.nih.gov/pubmed/34532490",
    "http://www.ncbi.nlm.nih.gov/pubmed/30805896",
    "http://www.ncbi.nlm.nih.gov/pubmed/33492986"
  ],
  "snippets": [
    {
      "text": "METHODS: Patients with advanced non-small cell lung cancer who were hospitalized in The Affiliated Cancer Hospital of Nanjing Medical University from October 2018 to August 2019 were selected to receive anti-PD-1 (pembrolizumab, sintilimab or toripalimab) monotherapy or combination regimens. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34521188",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we have presented a case of refractory ACC with lung metastases that was reduced after combinatorial treatment using the immune checkpoint inhibitor (ICI) toripalimab and anti-angiogenesis agent anlotinib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34532490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Toripalimab is a type of anti-PD-1 monoclonal antibody produced by Junshi Biosciences in China. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Case summary: Herein, we described for the first time a case report of SBSR induced by anti-PD-1 therapy in a cervical cancer patient. In addition, we revised existing literature on anti-PD-1 induced cutaneous reactions. We reported a cervical cancer patient who was treated with four successive cycles of Sintilimab and Toripalimab injections and developed systemic rashes, bullae, and epidermal desquamation, which worsened and led to infection, eventually causing death after being unresponsive to aggressive treatments. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34504425",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32943323",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Toripalimab (JS001) is IgG4 monoclonal antibody targeting PD-1, which has been approved for treatment of patients with metastatic melanoma after previous systemic therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32943323",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "mber of studies have confirmed that PD-1 inhibitors, including toripalimab, are not as effective in mucosal and acral melanomas as in non-acral cutaneous subtype. Tor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32406293",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our analysis reveals that toripalimab mainly binds to the FG loop of PD-1 with an unconventionally long complementarity-determining region 3 loop of the heavy chain, which is distinct from the known binding epitopes of anti-PD-1 mAbs with structural evidences.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we report the complex structure of PD-1 with toripalimab, a mAb that is approved by China National Medical Products Administration as a second-line treatment for melanoma and is under multiple Phase 1-Phase 3 clinical trials in both China and the US.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32487680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33492986",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: This is a first-in-human phase I study investigating the safety and efficacy of toripalimab, a humanized monoclonal antibody against the programmed cell death-1 (PD-1) receptor, in Chinese patients with advanced or recurrent malignant tumor refractory to standard trea",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224416",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "apy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of TMB and PD-L1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31236579",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd i",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30805896",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations. T",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32487680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445174",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "uentially. Toripalimab, a humanized IgG4 monoclonal antibody against programmed cell death protein-1 (PD-1), was approved by National Medical Product Administration in China in 2018 as second-line therapy for metastatic ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32406293",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445174",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30805896",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Toripalimab is an\u00a0anti-PD-1 monoclonal antibody used for the treatment of some cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34632814",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " with ICIs. Toripalimab is a type of anti-PD-1 monoclonal antibody produced by Junshi Bioscienc",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These findings benefit our understanding of the binding mechanisms of toripalimab to PD-1 and shed light for future development of biologics targeting PD-1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "a (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chem",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33492986",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " first dose of toripalimab.CONCLUSIONS: Toripalimab is a promising anti-PD-1 antibody, which was well tolerated and demonstrated anti-tumor activity in treatment-refrac",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32589350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "by immunohistochemistry. The patient was treated with toripalimab (a PD-1 inhibitor) concurrently with radiotherapy for bone metastases.OUTCOMES: Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34678907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Toripalimab, a humanized IgG4 monoclonal antibody (mAb) against programmed death receptor-1, is being extensively studied to treat various malignancies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34894461",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: Toripalimab is a promising anti-PD-1 antibody, which was well tolerated and demonstrated anti-tumor activity in treatment-refractory advanced solitary malignant tumors. Furt",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32589350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "JS001 (toripalimab) is a humanized IgG monoclonal antibody which strongly inhibits programmed cell death protein 1 (PD1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32874831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "sequentially. Toripalimab, a humanized IgG4 monoclonal antibody against programmed cell death protein-1 (PD-1), was approved by National Medical Product Administration in China in 2018 as second-line therapy for metastatic melanoma.AREAS COVERED: This is a comprehensive review of the literature and studies of toripalimab in melanoma, including clinical trials and translational research.EXPERT OPINION: Toripalimab is not inferior to pembrolizumab as a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32406293",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224416",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: This is a first-in-human phase I study investigating the safety and efficacy of toripalimab, a humanized monoclonal antibody against the programmed cell death-1 (PD-1) receptor, in Chinese patients with advanced or recurrent malignant tumor refractory to standard treatment.PATIENTS AND METHODS: During dose escalation, patients received a single-dose intravenous infusion of toripalimab for 56 days followed by multi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224416",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32589350",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "unotherapy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of TMB and PD-L1.PATIENTS AND METHODS: We reported on the AGC cohort of phase Ib/II trial evaluating the safety and activity of toripalimab in patients with AGC, oesophageal squamous cell carcinoma, nasopharyngeal carcinoma and head",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31236579",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31403867",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": []
}